Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma

S Sivakumar, FAS Lucas, TL McDowell, W Lang, L Xu… - Cancer research, 2017 - AACR
S Sivakumar, FAS Lucas, TL McDowell, W Lang, L Xu, J Fujimoto, J Zhang, PA Futreal…
Cancer research, 2017AACR
There is a dearth of knowledge about the pathogenesis of premalignant lung lesions,
especially for atypical adenomatous hyperplasia (AAH), the only known precursor for the
major lung cancer subtype adenocarcinoma (LUAD). In this study, we performed deep DNA
and RNA sequencing analyses of a set of AAH, LUAD, and normal tissues. Somatic BRAF
variants were found in AAHs from 5 of 22 (23%) patients, 4 of 5 of whom had matched LUAD
with driver EGFR mutations. KRAS mutations were present in AAHs from 4 of 22 (18%) of …
Abstract
There is a dearth of knowledge about the pathogenesis of premalignant lung lesions, especially for atypical adenomatous hyperplasia (AAH), the only known precursor for the major lung cancer subtype adenocarcinoma (LUAD). In this study, we performed deep DNA and RNA sequencing analyses of a set of AAH, LUAD, and normal tissues. Somatic BRAF variants were found in AAHs from 5 of 22 (23%) patients, 4 of 5 of whom had matched LUAD with driver EGFR mutations. KRAS mutations were present in AAHs from 4 of 22 (18%) of patients. KRAS mutations in AAH were only found in ever-smokers and were exclusive to BRAF-mutant cases. Integrative analysis revealed profiles expressed in KRAS-mutant cases (UBE2C, REL) and BRAF-mutant cases (MAX) of AAH, or common to both sets of cases (suppressed AXL). Gene sets associated with suppressed antitumor (Th1; IL12A, GZMB) and elevated protumor (CCR2, CTLA-4) immune signaling were enriched in AAH development and progression. Our results reveal potentially divergent BRAF or KRAS pathways in AAH as well as immune dysregulation in the pathogenesis of this premalignant lung lesion. Cancer Res; 77(22); 6119–30. ©2017 AACR.
AACR